tailieunhanh - Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic disease. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN